Immutep Ltd (PRRUF) — SEC Filings
Immutep Ltd (PRRUF) — 50 SEC filings. Latest: 6-K (Dec 23, 2025). Includes 47 6-K, 2 20-F, 1 SC 13G/A.
Overview
Immutep Ltd (PRRUF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 23, 2025: Immutep Ltd. filed a Form 6-K on December 23, 2025, reporting its status as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and has its principal executive offices in Sydney. This filing does not appear to contain specific financial updates o
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 48 neutral. The dominant filing sentiment for Immutep Ltd is neutral.
Filing Type Overview
Immutep Ltd (PRRUF) has filed 47 6-K, 2 20-F, 1 SC 13G/A with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PRRUF's 46 recent filings, 1 were flagged as high-risk, 3 as medium-risk, and 42 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Marc Voigt
Industry Context
The biotechnology sector, particularly in oncology, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Immutep are focused on novel immunotherapies, with a growing emphasis on combination treatments and targeting immune checkpoints like LAG-3. The competitive landscape includes large pharmaceutical companies and numerous smaller biotech firms vying for breakthroughs in cancer treatment.
Top Tags
sec-filing (27) · foreign-private-issuer (24) · 6-K (11) · company-update (7) · regulatory-filing (7) · corporate-update (6) · foreign-issuer (5) · disclosure (4) · reporting (4) · 6-k (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-35428 | Identifies the company's filing history with the SEC. |
| Net Loss | $61.4M | Increased from A$42.7 million in FY2024, representing a 43.8% rise in losses for FY2025. |
| Ordinary Shares Outstanding | 1,460,389,575 | As of June 30, 2025, indicating the current share count. |
| Ordinary Shares per ADS | 10 | Each American Depositary Share represents 10 ordinary shares. |
| LAG-3 Product Candidates | 5 | The total number of product candidates in Immutep's pipeline, including efti and IMP761. |
| French Corporate Tax Rate | 10% | Favorable tax rate for Immutep's French subsidiary for FY24, FY23, and FY22. |
| Acquisition Price | N/A | Specific dollar amount not disclosed in this filing, but funded by cash and potential raise. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immutep Ltd (PRRUF)?
Immutep Ltd has 50 recent SEC filings from Apr 2024 to Dec 2025, including 47 6-K, 2 20-F, 1 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRRUF filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 48 neutral. The dominant sentiment is neutral.
Where can I find Immutep Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immutep Ltd (PRRUF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immutep Ltd?
Financial highlights for Immutep Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PRRUF?
The investment thesis for PRRUF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immutep Ltd?
Key executives identified across Immutep Ltd's filings include Marc Voigt.
What are the main risk factors for Immutep Ltd stock?
Of PRRUF's 46 assessed filings, 1 were flagged high-risk, 3 medium-risk, and 42 low-risk.
What are recent predictions and forward guidance from Immutep Ltd?
Forward guidance and predictions for Immutep Ltd are extracted from SEC filings as they are enriched.